Skip to main content
. 2013 Jul 5;24(5):479–e114. doi: 10.1111/vde.12047

Table 4.

Concomitant medications*

Drug class Oclacitinib group [n = 216; n (%)] Placebo group [n = 220; n (%)]
Endectocides 145 (67.1) 150 (68.2)
Ectoparaciticides, insecticides and repellents 105 (48.6) 101 (45.9)
Canine vaccines 26 (12.0) 25 (11.4)
Glucosamine (with and without chondroitin) and nonsteroidal anti-inflammatory products 6 (2.8) 17 (7.7)
Systemic antibacterials§ 17 (7.9) 11 (5.0)
Omega-3 fatty acid preparations 7 (3.2) 7 (3.2)
Otologicals 13 (6.0) 6 (2.7)
Ophthalmologicals 2 (0.9) 5 (2.3)
*

Administered to ≥2% of the oclacitinib-treated dogs.

Administered in decreasing order of frequency in the oclacitinib treatment group.

Number and percentage are given on a per animal basis.

§

Administered during the continuation phase.